{"name":"Mikrobiomik Healthcare Company S.L.","slug":"mikrobiomik-healthcare-company-s-l","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"MBK-01","genericName":"MBK-01","slug":"mbk-01","indication":"Inflammatory bowel disease or related gastrointestinal inflammatory conditions (specific indication not publicly confirmed)","status":"phase_3"}]}],"pipeline":[{"name":"MBK-01","genericName":"MBK-01","slug":"mbk-01","phase":"phase_3","mechanism":"MBK-01 is a microbiome-based therapeutic that modulates the composition and function of the gut microbiota to restore immune homeostasis and reduce inflammation.","indications":["Inflammatory bowel disease or related gastrointestinal inflammatory conditions (specific indication not publicly confirmed)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi-AFBVV95cUxNUWxocS1uZjlveVdGRU85S0lMMDZ1cXZqNHVnNzRUdFZUVGFVWGVmNWtZTElMRTEwb1dlZ2FIT0tvRjlZMUJoTjgwSEtWX0l2aFdGRTgzUFROT3ZsajZEQ0RxSkQ3eDFtZWs3N3JoLWJpTURadkhLSkVYY09Kai02VXBvTUdJS2cyRkRmMlp4S0NVMXA5LVVLcm9Nc1I2R1RBTE5zUTBvckd0QWFYQWxjNFRVVlVIX0ZvSWRrWlhPTmtWT3NZR3hwejRIRDJZUlZxZ05pd0hFbEZndjBuYXllNE5yQThyckQ0dW91aEMyeEhpOWlBTEhKSQ?oc=5","date":"2026-04-07","type":"pipeline","source":"Barchart.com","summary":"Clostridium Difficile Infections Treatment Pipeline Shows Strong Momentum as 20+ Pharma Companies in the Race | DelveInsight - Barchart.com","headline":"Clostridium Difficile Infections Treatment Pipeline Shows Strong Momentum as 20+ Pharma Companies in the Race | DelveIns","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAJBVV95cUxNQnZaOHUwbWFabkV0RFAwSE4tQjNxVG5pNnFGWjFiNHlnbGI5SjBUc1pJblMydnpYN3NoV25ZcGlpdmdLM25nM0JHZVB1dnNGOGpvQjlhZ1Z3SFdFQjFPYWk3TnItRXJHeXRpTXctS1Q3RG5KVjF5MGVWX1d6eXM4RE5leUVMY0MtWUtoV0ZWeHZTb0UwZUM4bG95RkFUS25NWHdSVEwwRVF1OHNocUxiQTJvandOZ0J5aHpjVWlVRGpmYXNnbGtEcUZUQXJnN1Jmd0QxTjlvSFJKS21OY2djaVRhR2R2bnFQRHNBXzB4eDhTX3JNdnM5MWYzNk1Gc3p2WXcwakpNZlAzT3IyZzZaRjFhRG9MUGo5ZnNKODhVNWI4UXdqYV9JTTMtSDQtVEJKWHBvRm5ldDlWczFxWEdYaw?oc=5","date":"2025-09-02","type":"pipeline","source":"PR Newswire UK","summary":"Clostridioides difficile Infection Market Forecasts by DelveInsight Signal Groundbreaking Growth at a CAGR of 13.5% in the 7MM during the Forecast Period (2025-2034) - PR Newswire UK","headline":"Clostridioides difficile Infection Market Forecasts by DelveInsight Signal Groundbreaking Growth at a CAGR of 13.5% in t","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}